Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland

Kardiologia Polska

Volumn 71, Issue 12, 2013, Pages 1260-1265

  Bednarski, Janusz ^a   Cieszewska, Ewa ^a   Strzelecki, Aleksander ^a   Filipiak, Krzysztof J ^b  

^a Department of General Surgery   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Anticoagulation; Antiplatelet therapy; Atrial fibrillation; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN;

AGED; ALCOHOL ABUSE; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLAND; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; PLATELET AGGREGATION INHIBITORS; POLAND; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84890535600     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.a2013.0179     Document Type: Article

References (9)

1. Averinos JF, Brown RD, Foley DA et al. Cerebral events after diagnosis of mitral valve randomize. A community-based study of incident and predictive factors. Stroke, 2003; 34: 1339-1345.
2. Nasco E, Sherman DG, Talbert RL et al. Stroke prevention in atrial fibrillation investigators. Ann Intern Med, 2003; 138: 831-838.
3. Sandercock P, Bamford J, Dennis M et al. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet, 1993; 342: 1255-1262.
4. Van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA, 2002; 288: 2441-2448.
5. Zimetbaum PJ, Thosani A, Yu HT et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med, 2010; 123: 446-445.
6. Nieuwlaat R, Olsson SB, Lip GY et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation: the Euro Heart Survey on Atrial Fibrillation. Am Heart J, 2007; 153: 1006-1012.
7. Nieuwlaat R, Capucci A, Camm AJ et al. European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J, 2005; 22: 2422-2434.
8. Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace, 2009; 11: 423-434.
9. Szymanski FM, Puchalski B, Filipiak KJ. Obstructive sleep apnea, atrial fibrillation and erectile dysfunction - are they only coexisting conditions or a new clinical syndrome? Introduction of the OSAFED syndrome. Pol Arch Med. Wewn, 2013 Oct 9; DOI: pii:AOP-13-058.